Glenmark Pharmaceuticals Inc., USA (Glenmark) has announced that the United States Food & Drug Administration (FDA) granted final approval for amlodipine and olmesartan medoxomil tablets, 5 mg/20 mg, 5 mg/40 mg, 10 mg/20 mg, and 10 mg/40 mg, the generic version of Azor tablets, 5 mg/20 mg, 5 mg/40 mg, 10 mg/20 mg, and 10 mg/40 mg, of Daiichi Sankyo, Inc. a
According to IMS Health sales data for the 12 month period ending May 2017, the Azor tablets, 5 mg/20 mg, 5 mg/40 mg, 10 mg/20 mg, and 10 mg/40 mg market achieved annual sales of approximately $211.6 million.
Glenmark’s current portfolio consists of 119 products authorized for distribution in the US marketplace and 66 ANDA’s pending approval with the US FDA. In addition to these internal filings,
Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization headquartered at Mumbai, India. It is ranked among the top 75 pharma & biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2017).
Glenmark pharma, us fda final approval, generic azor tablets
